Moreover, there is evidence of a disruption of the immune checkpoint mechanisms in AML, with the upregulation of PD-L1 and other negative checkpoint molecules, such as CTLA-4 and LAG-3 [6]. This evidence concerns the gene CD274 and acute myeloid leukemia.